News

Clinical Trials Arena on MSN3d
First subject dosed in Vantage’s Phase II trial for diabetic retinopathy
Vantage Biosciences has dosed the first subject in the randomised Phase II trial of oral therapy VX-01 to treat ...
Vantage Biosciences Doses First Patient in Phase 2 Clinical Study of Oral VX-01 for Non-Proliferative Diabetic Retinopathy
Vantage Biosciences, a clinical stage biotechnology company advancing innovative therapies for diabetic eye diseases, today announced that the first patient has been successfully dosed in its Phase 2 ...
Medscape1y
Diabetic Retinopathy Management Guidelines
Diabetic retinopathy ... PDR: Proliferative DR; RCO: Royal College of Ophthalmologists. NHMRC Dilated ophthalmoscopy or slit-lamp biomicroscopy (dilated) with a lens or photography (non-mydriatic ...
Medical Dialogues13d
Glycemic Variability Marker Linked To Higher Neovascular Glaucoma Risk In Proliferative Diabetic Retinopathy Patients: Study
Researchers have observed in a new study that stress hyperglycemia (SHR) ratio could be a useful predictor of neovascular ...
PharmiWeb9d
Diabetic Retinopathy Market Size to Cross $15.1 Billion by 2035
The global Diabetic Retinopathy Market is valued at USD 9.1 Billion in 2024 and is projected to reach a value of USD 15.1 ...
Ophthalmology Times24y
Vantage Biosciences doses first patient in phase 2 study of VX-01, oral therapy for nonproliferative diabetic retinopathy
VX01-DR-201, is a phase 2, multicenter, double-masked, randomized, placebo-controlled study in patients with moderate to ...
Yahoo Finance7d
Vantage Biosciences Doses First Patient in Phase 2 Clinical Study of Oral VX-01 for Non-Proliferative Diabetic Retinopathy
an oral therapy for the treatment of non-proliferative diabetic retinopathy (NPDR). Diabetic retinopathy affects more than 100 million people worldwide and is one of the leading causes of ...